Abstract
This phase I/II trial studies the side effects and best dose of nivolumab when given with or
without ipilimumab to see how well they work in treating younger patients with solid tumors
or sarcomas that have come back (recurrent) or do not respond to treatment (refractory).
Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the
body's immune system attack the cancer, and may interfere with the ability of tumor cells to
grow and spread. It is not yet known whether nivolumab works better alone or with ipilimumab
in treating patients with recurrent or refractory solid tumors or sarcomas.
